Tuberculosis vaccine development: Strength lies in tenacity

Trends in Immunology

Volumn 33, Issue 7, 2012, Pages 373-379

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BCG VACCINE; DRUG CARRIER; VIRUS VECTOR;

ADJUVANT THERAPY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFORMATION; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MYCOBACTERIUM; NONHUMAN; REVIEW; TH1 CELL; TH17 CELL;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNIZATION, SECONDARY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84862640434     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.03.004     Document Type: Review

References (83)

1. Kaufmann S.H.E., Winau F. From bacteriology to immunology: the dualism of specificity. Nat. Immunol. 2005, 6:1063-1066.
2. La vaccination préventive contre la tuberculose par le " BCG" 1927, Masson, Paris, (in French). A. Calmette (Ed.).
3. Kaufmann S.H. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat. Immunol. 2008, 9:705-712.
4. Kaufmann S.H.E., et al. New vaccines for tuberculosis. Lancet 2010, 375:85-94.
5. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
6. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis. 2011, 11:633-640.
7. Kupferschmidt K. Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334:1488-1490.
8. Torrado E., et al. Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol. 2011, 32:66-72.
9. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 2009, 27:393-422.
10. Rohde K., et al. Mycobacterium tuberculosis and the environment within the phagosome. Immunol. Rev. 2007, 219:37-54.
11. Reece S.T., Kaufmann S.H. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis?. Curr. Opin. Microbiol. 2012, 15:63-70.
12. Ulrichs T., Kaufmann S.H.E. New insights into the function of granulomas in human tuberculosis. J. Pathol. 2006, 208:261-269.
13. Gengenbacher M., Kaufmann S.H.E. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 2012, 36:514-532.
14. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577.
15. Kaufmann S.H.E., Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr. Opin. Biotechnol. 2012, 10.1016/j.copbio.2012.03.007.
16. Horwitz M.A., et al. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009, 27:441-445.
17. Keyser A., et al. BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity. Vaccine 2011, 29:9308-9315.
18. Favorov M., et al. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan. PLoS ONE 2012, 7:e32567.
19. Grode L., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 2005, 115:2472-2479.
20. Dussurget O., et al. Molecular determinants of Listeria monocytogenes virulence. Annu. Rev. Microbiol. 2004, 58:587-610.
21. Desel C., et al. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J. Infect. Dis. 2011, 204:1573-1584.
22. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290:992-995.
23. Deretic V. Autophagy as an immune defense mechanism. Curr. Opin. Immunol. 2006, 18:375-382.
24. Winau F., et al. No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 2005, 10:707-715.
25. Jagannath C., et al. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med. 2009, 15:267-276.
26. Tsenova L., et al. BCG vaccination confers poor protection against M. tuberculosis HN878-induced central nervous system disease. Vaccine 2007, 25:5126-5132.
27. Horwitz M.A., et al. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:13853-13858.
28. Hoft D.F., et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 2008, 198:1491-1501.
29. Sun R., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
30. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 2001, 39:1681-1689.
31. Asensio J.A., et al. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert. Opin. Biol. Ther. 2008, 8:201-211.
32. Lee J.S., et al. Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host. Microbe 2008, 3:97-103.
33. Sambandamurthy V.K., et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006, 24:6309-6320.
34. Sweeney K.A., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 2011, 17:1261-1268.
35. Ligon L.S., et al. The ins and outs of Mycobacterium tuberculosis protein export. Tuberculosis (Edinb.) 2011, 10.1016/j.tube.2011.11.005.
36. Von Eschen K., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vacc. 2009, 5:475-482.
37. Dietrich J., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 2005, 174:6332-6339.
38. van Dissel J.T., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
39. Diel R., et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur. Respir. J. 2011, 37:88-99.
40. Aagaard C., et al. A multistage tuberculosis vaccine that confers efficient protection pre- and post-exposure. Nat. Med. 2011, 17:189-194.
41. Bertholet S., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2010, 2:53ra74.
42. McShane H., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 2004, 10:1240-1244.
43. Santosuosso M., et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 2006, 74:4634-4643.
44. Abel B., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J Respir. Crit. Care Med. 2010, 181:1407-1417.
45. Hill A.V., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 2010, 6:78-83.
46. Flatz L., et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 2010, 16:339-345.
47. Hatherill M., et al. The potential impact of helminth infection on trials of novel tuberculosis vaccines. Vaccine 2009, 27:4743-4744.
48. Hesseling A.C., et al. The risk of disseminated Bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007, 25:14-18.
49. Woolhouse M.E., et al. Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat. Genet. 2002, 32:569-577.
50. Jeffares D.C., et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat. Genet. 2007, 39:120-125.
51. Kawashima Y., et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009, 458:641-645.
52. McLellan J.S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
53. Kwong P.D., et al. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 2011, 1:a007278.
54. Wu X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
55. Brennan M.J., Delogu G. The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol. 2002, 10:246-249.
56. Talarico S., et al. Association of Mycobacterium tuberculosis PE PGRS33 polymorphism with clinical and epidemiological characteristics. Tuberculosis (Edinb.) 2007, 87:338-346.
57. Comas I., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 2010, 42:498-503.
58. Aagaard C.S., et al. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J. Immunol. 2009, 183:2659-2668.
59. Mollenkopf H.J., et al. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guérin induce equal protection. J. Infect. Dis. 2004, 190:588-597.
60. StopTB Partnership and WHO (2011) The Global Plan to Stop TB 2011-2015.
61. Dorhoi A., Kaufmann S.H. Fine-tuning of T cell responses during infection. Curr. Opin. Immunol. 2009, 21:367-377.
62. van der Wel N., et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298.
63. Winau F., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24:105-117.
64. Schaible U.E., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat. Med. 2003, 9:1039-1046.
65. De Libero G., Mori L. Recognition of lipid antigens by T cells. Nat. Rev. Immunol. 2005, 5:485-496.
66. Lewinsohn D.A., et al. Views of immunology: effector T cells. Immunol. Rev. 2011, 240:25-39.
67. Joosten S.A., et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 2010, 6:e1000782.
68. Scotet E., et al. Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk. Front. Biosci. 2008, 13:6872-6885.
69. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
70. Potian J.A., et al. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 2011, 208:1863-1874.
71. Zhu J., et al. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 2010, 28:445-489.
72. Korn T., et al. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
73. Khader S.A., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007, 8:369-377.
74. Cruz A., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 2010, 207:1609-1616.
75. Urdahl K.B., et al. Initiation and regulation of T-cell responses in tuberculosis. Mucosal. Immunol. 2011, 4:288-293.
76. Belkaid Y., Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu. Rev. Immunol. 2009, 27:551-589.
77. Stenger S., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
78. Joosten S.A., et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8029-8034.
79. Maglione P.J., Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 2009, 39:676-686.
80. Johnson C.M., et al. Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Tuber. Lung Dis. 1997, 78:257-261.
81. Neves P., et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 2010, 33:777-790.
82. Lingnau K., et al. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev. Vaccines 2007, 6:741-746.
83. Christensen D., et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 2010, 390:19-24.